ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. following an 83% drop in stock price after the failure of its drug trial for Efzofitimod, which did not meet its primary endpoint [1][2][3]. Summary by Relevant Sections Allegations - The lawsuit claims that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [2][3]. - The firm alleges that aTyr concealed critical adverse facts about the drug's ability to allow patients to taper off steroids, which is a key measure of its efficacy [3][4]. Legal Focus - The primary legal focus is whether aTyr misrepresented the drug's true ability to help patients reduce steroid dependency, particularly in light of the failed primary endpoint in the Phase 3 EFZO-FIT study [5]. - The investigation is centered on the discrepancy between the company's optimistic public statements and the actual performance of the drug in clinical trials [4][5]. Market Impact - Following the announcement of the trial failure, aTyr's stock plummeted from $6.03 to $1.02, representing an 83.2% loss on September 15, 2025 [5]. - The lawsuit seeks to determine if investors are entitled to damages due to the alleged wrongful acts and omissions by the company [5]. Next Steps for Investors - Investors who purchased aTyr shares during the class period (November 7, 2024, through September 12, 2025) and experienced significant losses are encouraged to submit their claims by the December 8, 2025 deadline [6].